Improved Conjugate Vaccines Derived from a Bacterial Immunomodulatory Protein

Project: Research council

Project Details


TB remains a major health and economic burden. Key discoveries (University of Bath) and initial vaccination studies (Newcastle University) have established that a bacterial protein known as Sbi (from Staphylococcus aureus) can improve immune responses to a TB fragment. What makes our Sbi pro-vaccines an attractive commercial opportunity is our findings that Sbi can locally activate the innate immune system of all mammals tested to date. As such, vaccines developed using Sbi could be used across multiple species, including cattle and humans. Here, we will establish how successful Sbi conjugates/compounds are at generating an appropriate adaptive immune response against TB. These studies will lead to full TB challenge experiments in the future, which will allow us to confirm Sbi conjugates as highly effective multifunctional vaccines for animals; providing a clear pathway to commercialization of novel Sbi conjugate based vaccines to improve animal health and world food security.
Effective start/end date10/10/169/07/18


  • Biotechnology and Biological Sciences Research Council

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.